Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Total Current Liabilities (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Total Current Liabilities for 5 consecutive years, with $21.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 2.32% year-over-year to $21.2 million, compared with a TTM value of $21.2 million through Dec 2025, down 2.32%, and an annual FY2025 reading of $21.2 million, down 2.32% over the prior year.
  • Total Current Liabilities was $21.2 million for Q4 2025 at Aligos Therapeutics, down from $22.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $41.4 million in Q1 2022 and bottomed at $18.9 million in Q1 2024.
  • Average Total Current Liabilities over 5 years is $26.7 million, with a median of $24.6 million recorded in 2021.
  • The sharpest move saw Total Current Liabilities skyrocketed 63.91% in 2022, then tumbled 32.76% in 2024.
  • Year by year, Total Current Liabilities stood at $39.0 million in 2021, then decreased by 14.96% to $33.1 million in 2022, then decreased by 27.84% to $23.9 million in 2023, then fell by 9.07% to $21.7 million in 2024, then dropped by 2.32% to $21.2 million in 2025.
  • Business Quant data shows Total Current Liabilities for ALGS at $21.2 million in Q4 2025, $22.0 million in Q3 2025, and $20.3 million in Q2 2025.